At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 93 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
Placebo 200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double-Blind, Placebo-Controlled, Parallel-Cohort Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Once-Daily Application of Topical VDA-1102 Ointment for 28 Days in Subjects With Actinic Keratosis
In Brief
A Phase 2 clinical trial evaluating Placebo, 5% VDA-1102, and 1 other intervention for Actinic Keratosis. Completed, enrolled 93 participants across 1 site.
Detailed Summary
This Phase 2 clinical trial is a multi-center, randomized, double-blind, placebo-controlled, multiple-dose, parallel-cohort study to assess the efficacy, safety and tolerability of VDA-1102 in the treatment of actinic keratosis (AK) on the head of male and female adult subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsActinic Keratosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartJul 2016
First PostedJul 2016
Primary CompletionMay 2017
TodayJul 2026
First PostedJul 26, 2016
Enrollment StartJul 15, 2016
Primary CompletionMay 26, 2017
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 9.9 years ago
Interventions
Placebodrug
200 mg applied once-daily for 28 days
5% VDA-1102drug
200 mg applied once-daily for 28 days
10% VDA-1102drug
200 mg applied once-daily for 28 days